So what hap­pened with No­var­tis Gene Ther­a­pies? Here's your an­swer

Over the last cou­ple of days it’s be­come clear that the gene ther­a­py di­vi­sion at No­var­tis has qui­et­ly un­der­gone a ma­jor re­or­ga­ni­za­tion. We learned on Mon­day that Dave Lennon, who had pur­sued a high-pro­file role as pres­i­dent of the unit with 1,500 peo­ple, had left the phar­ma gi­ant to take over as CEO of a start­up.

Like a lot of the ma­jors, No­var­tis is an open high­way for head hunters, or any­one look­ing to staff a start­up. So that was news but not com­plete­ly un­ex­pect­ed.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN